Literature DB >> 7636169

Infections caused by Staphylococcus aureus in a Veterans' Affairs nursing home care unit: a 5-year experience.

S J Spindel1, L J Strausbaugh, C Jacobson.   

Abstract

OBJECTIVES: To describe the frequency and patterns of infection caused by methicillin-susceptible Staphylococcus aureus (MSSA) and methicillin-resistant S aureus (MRSA) infections in a single nursing home population and to determine the effect of MRSA's entry into the facility on subsequent experience with both MSSA and MRSA infections.
DESIGN: Observational and descriptive. Surveillance data on nursing home-acquired infections were reviewed to identify all patients with MSSA and MRSA infections occurring during the 5-year period from 1987 to 1991. The medical records of these patients were reviewed retrospectively to collect additional information about the patients and their infections. SETTING AND PATIENTS: A 120-bed Veterans' Affairs nursing home care unit (NHCU) whose residents predominantly were elderly men with severe underlying diseases and functional impairments.
RESULTS: During the 5-year study period, 40 MSSA and 28 MRSA infections were acquired by NHCU residents. Twelve to 19 S aureus infections occurred each year. S aureus accounted for 13% to 17% of all NHCU-acquired infections during the years of study, occurring with a frequency of 0.29 to 0.47 infections per 1,000 resident-care days. MRSA infections, first detected in 1988, accounted for an increasing percentage of S aureus infections in subsequent years, but this increase had little effect on the facility's overall infection rates, the composite S aureus infection rates, or the types of infections observed. MSSA and MRSA infections acquired in the NHCU were comparable. Both affected patients with severe underlying diseases and functional impairments. Pneumonia, urinary tract infections, skin and soft tissue infections, and conjunctivitis were the types of infections observed most frequently, accounting for 28%, 25%, 22%, and 15% of all S aureus infections, respectively. Four bacteremic infections occurred in the MSSA group, and five in the MRSA group (P = .47). Four of the MSSA and three of the MRSA infections resulted in death (P = 1.0). Nine of the MSSA and 12 of the MRSA infections resulted in the patient's transfer to the associated acute care hospital for additional care (P = .13).
CONCLUSIONS: In the NHCU setting, MSSA and MRSA infections were similar in terms of the types of residents affected, the sites involved, and the frequency of adverse outcomes. The entry of MRSA into the facility appeared to have no effect on the subsequent experience with NHCU-acquired infections caused by S aureus.

Entities:  

Mesh:

Year:  1995        PMID: 7636169     DOI: 10.1086/647093

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Is methicillin-resistant Staphylococcus aureus replacing methicillin-susceptible S. aureus?

Authors:  Elizabeth Mostofsky; Marc Lipsitch; Gili Regev-Yochay
Journal:  J Antimicrob Chemother       Date:  2011-07-07       Impact factor: 5.790

2.  Methicillin-resistant Staphylococcus aureus infections of the eye and orbit (an American Ophthalmological Society thesis).

Authors:  Preston Howard Blomquist
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 3.  Methicillin-resistant Staphylococcus aureus in nursing homes. Epidemiology, prevention and management.

Authors:  S F Bradley
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 4.271

4.  Nosocomial keratitis caused by methicillin-resistant Staphylococcus aureus: case report and preventative measures.

Authors:  Puneet S Braich; Shruti Aggarwal; Sabrina Mukhtar; David Rp Almeida
Journal:  J Community Hosp Intern Med Perspect       Date:  2015-10-19

5.  Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: a retrospective study.

Authors:  Saoraya Lueangarun; Amorn Leelarasamee
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-08-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.